CMPS Company Profile and Key Details

CMPS has shown sold momentum, gaining 4.43% over the past week and 12.12% over the past quarter, though year-to-date performance is up 5.94%. Short-term trend indicators are bearishly aligned (SMA20 4.09%, SMA50 17.15%, SMA200 47.35%). The stock’s 14-day RSI is 57.24 (neutral), while the ATR of 0.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -10.85% below its high and over 224.89% above its low. Average 10-day trading volume of 1.23 million shares is below the 3-month average of 1.60 million, indicating normal recent market interest.

COMPASS Pathways plc has 95.94 million shares outstanding. The public float is 58.41 million shares, elevated short interest at 8.26% of float. This equals 7.78 million shares. The short ratio is 4.18 days. Institutional investors hold 64.17% of the float. Insiders own 13.3%. ATAI Life Sciences N.V. holds 6.91 million shares, Malievskaia Ekaterina has 3.15 million shares and Goldsmith George Jay has 3.15 million shares.

COMPASS Pathways plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.97. This means the shares are trading above this model’s fair value.

COMPASS Pathways plc (NASDAQ:CMPS) closed at $6.99 USD, losing -$0.32 (-4.45%) from the previous close of $7.31. The stock is currently mid-range between its 52-week high and low $2.25 and $8.20. With a market capitalization of about $670.57 million, COMPASS Pathways plc is classified as a small-cap and shows higher-than-market volatility (beta ~1.93). Key stats such as the average daily volume over the past year has been around 1.64 million shares, in line with its 52-week average. Headquartered in London, None, COMPASS Pathways plc operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Kabir Kumar Nath, the company employs approximately 166 people and listed since September 18, 2020. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States.

Wall Street analysts project EPS growth of 9.82% annually over the next five years. The latest quarter delivered EPS of -$1.44. The next quarter is forecast at -$0.40. Next year's EPS is expected at -$2.31. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 8 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $6.00. The high target offers 515.6% upside. The low target suggests -17.92% downside. The mean target is $24.20. This offers 231.05% upside. COMPASS Pathways plc earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by 261.13%. The prior quarter beat by 2.7%. Over the last six quarters, Apple has recorded several small beats. These include -99.89% in August 01, 2024.

Our AI price prediction model suggests that COMPASS Pathways plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.7%, with price expected at $7.80 by February 03, 2026, within a range of $7.37 to $8.22 3-Month Outlook: Projected rise of 29.0%, reaching $9.43 by April 16, 2026, with a range of $9.28 to $9.60. 1-Year Outlook: Projected gain of 366.76%, with price at $34.12 by January 15, 2027, within a range of $27.15 to $45.24.

COMPASS Pathways plc (NASDAQ:CMPS) shares are flat 5.94% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows COMPASS Pathways plc trading at a premium to the broader market with a P/E of -2.91. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $49.79, suggesting 581.12% upside. Our AI forecast model points to short-term strength (6.7% over two weeks), a medium-term rise (29.0% over three months), and a longer-term gain (366.76% over one year), with expected trading ranges indicating moderate volatility.

COMPASS Pathways plc trades at a P/E ratio of -2.91, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 18.39 reflecting a rich premium to book value. The P/FCF stands at -4.32, also below market averages. Compared to sector medians, COMPASS Pathways plc P/S is trading at a discount to the sector, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.